POLICYBZR

PB Fintech, or Policybazaar, has certainly caught attention with its recent performance. The company has demonstrated robust multi-year growth, clocking nearly 39% CAGR in insurance premiums and an impressive 41% CAGR in lending disbursals. The latest Q2 results further underscore this momentum, with revenue climbing 38% and a remarkable over 200% year-on-year jump in PAT to ₹220 crore. This marks a significant turnaround, shifting from deep losses in FY22 (around -73% PAT margin) to a healthy +8% margin. The recent GST exemption on health and life insurance is a key tailwind. This move is expected to enhance affordability, potentially encouraging customers to opt for higher sum assured, thereby increasing ticket sizes. Management’s ambitious target of ₹1 lakh crore in premiums with a 3% PAT margin suggests a clear long-term vision. This growth trajectory, if sustained, could significantly boost EPS and justify what currently appears as a high headline PE over time, typical for high-growth enterprises. My Take: For investors, this narrative presents a compelling case for a growth stock. The pivot to profitability, coupled with strong underlying business expansion and a favorable regulatory environment, suggests a robust foundation. While high-growth stocks always carry risk, PB Fintech's trajectory indicates a promising outlook for long-term capital appreciation.